NCT01129349已完成1 期
A Phase 1, Open-label, Dose Escalation Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 44
- 试验地点
- 3
- 主要终点
- Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD)
研究概览
简要总结
To evaluate the safety and tolerability of Oprozomib in patients with advanced refractory or recurrent solid tumors including determination of its Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD) To determine the pharmacokinetics (PK) of Oprozomib To explore the anti-tumor activity of Oprozomib in this patient population including the overall response rate (ORR), the duration of responses (DOR), the progression-free survival (PFS) and time to progression (TTP) To define the pharmacodynamics (PDn) of Oprozomib.
详细描述
This is a Phase 1, open label, dose-escalation study to determine the safety, MTD, and PK/PDn of Oprozomib when administered orally (PO) on Days 1, 2, 3, 4, and 5 of a 14 day cycle in patients with advanced refractory or recurrent solid tumor malignancies for which standard curative measures do not exist or are no longer effective.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Disease Related
- •Histologically confirmed advanced solid tumor that is refractory or recurrent after standard treatments.
- •At least one site of radiographically measurable disease of ≥ 2 cm in the largest dimension by traditional computed tomography (CT) scanning technique or ≥ 1 cm in the largest dimension by spiral CT scanning (per RECIST criteria); or if, in the Principal Investigator's opinion, evaluable disease can be reliably and consistently followed, the patient may be eligible upon approval by the Onyx Therapeutics, Inc., Medical Monitor.
- •Demographic
- •Males and females ≥ 18 years of age
- •Life expectancy of more than three months
- •Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- •Laboratory
- •Adequate hepatic function, with bilirubin ≤ 1.5 times the upper limit of normal (ULN), and alanine aminotransferase (ALT) ≤ 3 times ULN or ≤ 5 times ULN in the presence of hepatic tumor involvement
- •Absolute neutrophil count (ANC) ≥ 1500/mm3, hemoglobin ≥ 8 g/dL, and platelet count ≥ 100,000/ mm3
- •Screening platelet count must be independent of platelet transfusions for at least one week
- •Screening ANC must be independent of granulocyte- and granulocyte/macrophage colony stimulating factor (G-CSF and GM-CSF) support for at least one week and of pegylated G-CSF for at least two weeks
- •Patients may receive red blood cell (RBC) transfusions or receive supportive care with erythropoietin or darbepoetin in accordance with institutional guidelines
- •Calculated or measured creatinine clearance of ≥ 30 mL/min; calculation using a generally accepted formula such as that of Cockcroft and Gault: CrCl = [(140 - Age) × Mass (kg) / (72 × Creatinine mg/dL)], multiply by 0.85 if female
- •Ethical / Other
- •Written informed consent in accordance with federal, local, and institutional guidelines
- •Female patients of childbearing potential must have a negative serum or urine pregnancy test within three days of the first dose and agree to use dual methods of contraception during the study and for one month following the last dose of study drug. Post-menopausal females (> 45 years old and without menses for > 1 year) and surgically sterilized females are exempt from these requirements. Male patients must use an effective barrier method of contraception during the study and for one month following the last dose if sexually active with a female of childbearing potential.
排除标准
- •Disease Related
- •Chemotherapy with approved or investigational anticancer therapeutics, including steroid therapy, within four weeks prior to first dose of Oprozomib or six weeks for antibody therapy
- •Radiation therapy or immunotherapy within three weeks prior to first dose; localized radiation therapy within one week prior to first dose Patients with brain metastases (patients with prior brain metastases are permitted, but must have completed treatment and have no evidence of active CNS disease for at least three months prior to first dose)
- •Prior treatment with a proteasome inhibitor
- •Concurrent Conditions
- •Major surgery within three weeks prior to first dose
- •Congestive heart failure (New York Heart Association Class III to IV), symptomatic ischemia, or conduction abnormalities. Conduction system abnormalities not clinically warranting intervention are allowed.
- •Myocardial infarction within three months prior to first dose
- •Active infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose
- •HIV infection (HIV seropositive)
- •Active hepatitis A, B, or C infection
- •Peripheral neuropathy of Grade ≥ 3 or Grade 2 with pain at the time of the first dose
- •Patients with pleural effusions requiring repeat thoracentesis or ascites requiring repeat paracentesis
- •Prior Oprozomib therapy
- •Hypersensitivity to Oprozomib or any of its components
- •Ethical / Other
- •Female patients who are pregnant or lactating
- •Psychiatric or medical conditions that in the opinion of the Investigator could interfere with treatment
研究组 & 干预措施
Oprozomib
Experimental
Phase I, Dose Escalation, Single Arm, Open Label
干预措施: Oprozomib (Drug)
结局指标
主要结局
Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD)
时间窗: 31 months
* To evaluate the safety and tolerability of Oprozomib in patients with advanced refractory or recurrent solid tumors including determination of its Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD) * To determine the pharmacokinetics (PK) of Oprozomib
次要结局
- Overall response rate (ORR), duration of responses (DOR), progression-free survival (PFS), and time to progression (TTP)(31 months)
研究者
研究点 (3)
Loading locations...
相似试验
招募中
1 期
OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver CancerAdvanced Liver CancerNCT05698459Binhui Biopharmaceutical Co., Ltd.12
撤回
1 期
Safety and Immunogenicity Study of GX-70 in TB PatientPulmonary TuberculosesHigh Risk Factors for RelapseTreatment FailureNCT03159975Yonsei University
已完成
1 期
Study of ALXN1850 in Participants With Hypophosphatasia (HPP)HypophosphatasiaNCT04980248Alexion Pharmaceuticals, Inc.15
终止
1 期
Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273Infectious DiseaseCOVID-19NCT05420077RVAC Medicines (US), Inc.13
已完成
1 期
A Phase I Study of CS1002 in Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT04338724CStone Pharmaceuticals6